Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Recurrence 2Carcinoma, Non-Small-Cell Lung 2Neoplasm Metastasis 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1Leiomyosarcoma 1Hodgkin Disease 1

Interventions

Cyclophosphamide 82fludarabine phosphate 68Mycophenolic Acid 59Whole-Body Irradiation 52Peripheral Blood Stem Cell Transplantation 51Tacrolimus 49Melphalan 44Etoposide 42Busulfan 39fludarabine 36Rituximab 36Filgrastim 36Granulocyte Colony-Stimulating Factor 35Brentuximab Vedotin 33Cyclosporine 32Doxorubicin 28Methotrexate 27Antilymphocyte Serum 27Radiotherapy 24Dacarbazine 19Vinblastine 18Nivolumab 18Cytarabine 18Prednisone 16Carmustine 16thymoglobulin 15Stem Cell Transplantation 15Sirolimus 15Alemtuzumab 14Vincristine 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Hodgkin Disease × mocetinostat × Clear all
NCT02429375 2022-05-12

Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
7 enrolled 10 charts
Lymphoid

Hodgkin Disease, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡